Rappta Therapeutics

OverviewSuggest Edit

Rappta Therapeutics is a company that develops anti-cancer drugs. The company works on anti-cancer molecules to therapeutically reactivate PP2A, a critical enzyme regulating protein de-phosphorylation and tumor growth.
TypePrivate
Founded2006
HQHelsinki, FI
Websiterappta-therapeutics.com

Latest Updates

Employees (est.) (Jan 2022)10
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Rappta Therapeutics

George Trainor

George Trainor

Head of Chemistry
Goutham Narla

Goutham Narla

Chief Scientific Officer
Pekka Kallio

Pekka Kallio

Head of Operations
Derek Taylor

Derek Taylor

Head of Structural Biology
Jukka Hiltunen

Jukka Hiltunen

Head of IP
Jeroen Bakker

Jeroen Bakker

Board Member
Show more

Rappta Therapeutics Office Locations

Rappta Therapeutics has an office in Helsinki
Helsinki, FI (HQ)
Haartmaninkatu 4, Building 14
Show all (1)

Rappta Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2006

Rappta Therapeutics total Funding

$10.6 m

Rappta Therapeutics latest funding size

$10.63 m

Time since last funding

a year ago

Rappta Therapeutics investors

Rappta Therapeutics's latest funding round in October 2020 was reported to be $10.6 m. In total, Rappta Therapeutics has raised $10.6 m
Show all financial metrics

Rappta Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

94/100

SecurityScorecard logo

Rappta Therapeutics Online and Social Media Presence

Embed Graph

Rappta Therapeutics News and Updates

Rappta Therapeutics Appoints Sunjeet Sawhney as Chief Executive Officer

HELSINKI and LONDON, Sept. 15, 2021 /PRNewswire/ -- Rappta Therapeutics ("Rappta"), which is focused on developing first-in-class anti-cancer drugs reactivating protein phosphatase 2A (PP2A), announces today the appointment of Sunjeet Sawhney as Chief Executive Officer (CEO) with...

Rappta Therapeutics Closes €9M Series A Financing

Rappta Therapeutics, a Helsinki, Finland-based company focused on developing first-in-class anti-cancer drugs activating protein phosphatase 2A (PP2A), closed a €9m Series A financing.

Rappta Therapeutics Frequently Asked Questions

  • When was Rappta Therapeutics founded?

    Rappta Therapeutics was founded in 2006.

  • Who are Rappta Therapeutics key executives?

    Rappta Therapeutics's key executives are George Trainor, Goutham Narla and Pekka Kallio.

  • How many employees does Rappta Therapeutics have?

    Rappta Therapeutics has 10 employees.

  • Who are Rappta Therapeutics competitors?

    Competitors of Rappta Therapeutics include Takeda Oncology, Shanghai Junshi Biosciences and Ethypharm.

  • Where is Rappta Therapeutics headquarters?

    Rappta Therapeutics headquarters is located at Haartmaninkatu 4, Building 14, Helsinki.

  • Where are Rappta Therapeutics offices?

    Rappta Therapeutics has an office in Helsinki.

  • How many offices does Rappta Therapeutics have?

    Rappta Therapeutics has 1 office.